Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Gut Microbes|May 1, 2018
Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndromeAnthony A Fodor, Mark Pimentel, William D Chey, et al.Journal of Clinical Pharmacology|April 16, 2005
Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humansChun-Su Yuan, Harold Doshan, Martha R Charney, et al.Microorganisms|June 27, 2024
Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 PneumoniaGiulia Morsica, Emanuela Messina, Sabrina Bagaglio, et al.Journal of Drug Assessment|August 19, 2016
Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileusEugene R Viscusi, James P Rathmell, Alessandro Fichera, et al.Journal of Pain and Symptom Management|April 29, 2008
Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging studyRussell K Portenoy, Jay Thomas, Michele L Moehl Boatwright, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 24, 2022
Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled TrialsJasmohan S Bajaj, Tarek I Hassanein, Nikolaos T Pyrsopoulos, et al.The New England Journal of Medicine|May 30, 2008
Methylnaltrexone for opioid-induced constipation in advanced illnessJay Thomas, Sloan Karver, Gail Austin Cooney, et al.Journal of the American Academy of Dermatology|October 8, 2017
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trialsMark G Lebwohl, Kim A Papp, Lauren B Marangell, et al.Antimicrobial Agents and Chemotherapy|January 27, 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542Jeffrey M Jacobson, Robert J Israel, Israel Lowy, et al.The Prostate|January 22, 2019
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancerDaniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, et al.Pageof 5